BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Victoza liraglutide regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending use of 1.2 mg Victoza liraglutide from Novo Nordisk to treat Type II diabetes in triple therapy regimens (in combination with metformin and a sulfonylurea or thiazolidinedione). The committee...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >